MBX Biosciences CFO Richard Bartram resigns; John Smither named interim CFO

MBX Biosciences, Inc.

CFO Richard Bartram resigns effective March 15, 2026; will serve as consultant post-resignation.
John Smither appointed Interim CFO effective March 16, 2026; base salary $325k, target bonus 40%, $25k sign-on.
Lease entered for 13,642 sqft office/lab in Burlington, MA; aggregate base rent ~$3.4M over 4-year term.
Departure not due to dispute; search for permanent CFO underway.

item 1.01item 9.01item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.